Relatlimab, a humanized IgG4 monoclonal antibody developed by Bristol-Myers Squibb (BMS), targets LAG-3, inhibiting its interaction with MHC-II and thereby restoring T cell function to attack and eliminate tumor cells. Here, LAG3 is linked to neoplasm.